Education
About Us
Working with TipRanks
Follow Us
Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
Earnings Data
Report Date
Jun 03, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated clear positive momentum driven by the October 2025 FDA clearance, a major professional society recommendation (ASBRS), record 2025 revenue ($3.4M) and expanding global and U.S. commercial interest with a growing pipeline and planned expansion of the U.S. sales force. Near-term catalysts include the PMS rollout, transitional pass-through payment and pursuit of CPT1 physician reimbursement, all of which could materially accelerate adoption if achieved. Offsetting risks are execution and timing uncertainties around PMS site conversion, broader reimbursement finalization, regional regulatory approvals (Health Canada, Japan) and limited disclosed detail on production ramp. Overall, the highlights (regulatory validation, society endorsement, revenue records, clinical/publication momentum and expanding pipeline) substantially outweigh the operational and timing lowlights.Company Guidance
Record Revenue and Quarterly Sales
Reported record fourth-quarter sales of approximately $1.3 million and record full-year revenue from sales of $3.4 million for the twelve months ended December 31, 2025.
U.S. FDA Clearance for ProSense
ProSense received U.S. FDA marketing authorization (October 2025) for treatment of low-risk breast cancer in women age 70+ and patients not suitable for surgery — positioning ProSense as the first and only FDA-cleared medical device for breast cancer cryoablation in the U.S.
Major Medical Society Endorsement
American Society of Breast Surgeons (ASBRS) 2026 guidance now recommends cryoablation as an option for selected biologically low-risk early-stage breast cancer, a validation expected to catalyze adoption and support reimbursement expansion.
Growing U.S. Commercial Momentum and Pipeline
Company reports a growing pipeline of customers converting to signed contracts, deliveries and installations (examples include Fuel Imaging and Thomas Hospital), and expects an increase in system sales and installations starting in Q2 2026 with continued growth thereafter.
Post-Marketing Study (PMS) Planning and Enrollment Targets
FDA requires 30 hybrid PMS sites; majority of the 30 sites have been identified. Onboarding expected in the next 3–6 months with all 30 opened by end of next year; patient enrollment slated to commence late summer with a target of 20% enrollment by this time next year.
Existing Reimbursement and Potential Upside
Procedures currently covered by an existing CPT facility payment of about $4,000. Company has applied for transitional pass-through payment that could add up to $900 per procedure by early 2027, and plans to file for CPT1 physician reimbursement in Q2 2026 (target effective early 2028).
Global Regulatory and Clinical Expansion
Submitted Class III amended application to Health Canada for expanded indication (treatment of early-stage low-risk invasive breast cancer in patients aged 60+); working with Terumo in Japan (PMDA consultation completed with positive outcomes) and seeing increased international demand and adoption following U.S. FDA clearance.
Strong Scientific and Awareness Momentum
Record number of peer-reviewed publications and presentations in 2025 (60 principal investigators at 10 conferences) with ongoing independent studies (SIXT in Brazil, PRECISE in Italy) and active social media promotion to boost patient recruitment and professional awareness.
Commercial Team Expansion
Plan to triple the U.S. commercial team by the end of 2026 to address rising demand (targeted ~3x growth in sales headcount).
ICCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 17, 2026 | $0.73 | $0.67 | -8.90% |
Nov 19, 2025 | $0.72 | $0.70 | -2.78% |
Aug 13, 2025 | $0.82 | $0.84 | +2.44% |
May 28, 2025 | $1.11 | $1.01 | -9.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Icecure Medical Ltd. (ICCM) report earnings?
Icecure Medical Ltd. (ICCM) is schdueled to report earning on Jun 03, 2026, Before Open (Confirmed).
What is Icecure Medical Ltd. (ICCM) earnings time?
Icecure Medical Ltd. (ICCM) earnings time is at Jun 03, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCM EPS forecast?
ICCM EPS forecast for the fiscal quarter 2026 (Q1) is -0.05.